Studies of the efficacy of Ribonucleotide Reductase inhibition in preclinical models of Acute Myeloid Leukemia in combination with standard and novel therapeutics

Acute Myeloid Leukemia (AML) is an aggressive disease of the marrow with approximately 18,800 new cases each year. The elderly population represents the bulk of AML patients with a median age of onset of 70. More than 70% of AML patients are over the age of 60, and for this group the 5 year overall survival rate is under 10%. There are multiple reasons for this, including complex karyotypes in elderly patients, other comorbidities, and chemoresistance. This group of patients needs more effective chemotherapeutic options.

Grantor dc:publisher

Wake Forest University

Year dc:date.issued

2015

Author dc:creator

• Cook, Guerry

• Acute Myeloid Leukemia

Language dc:language.iso

en

Handle dc:identifier.uri

http://hdl.handle.net/10339/57136

OAI identifier oai:identifier

oai:wakespace.lib.wfu.edu:10339/57136